Phio Pharmaceuticals Corp PHIO
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if PHIO is a good fit for your portfolio.
News
-
Phio Pharmaceuticals Reports Q1 2024 Results and Provides Business Update
-
Phio Pharmaceuticals Announces Upcoming Presentation at the Annual Meeting of the Society of Clinical Oncology (ASCO)
-
Intratumoral Injection of Phio’s PH-762 significantly inhibits tumor growth in murine tumor models and may generate memory-specific T cells
-
Phio Pharmaceuticals Announces Upcoming Presentations at the 81st Annual Meeting of the Society for Investigative Dermatology (SID)
-
Phio Pharmaceuticals Announces Upcoming Presentation at the 27th Annual Meeting of the American Society of Cell and Gene Therapy (ASCGT)
-
National Spotlight Features Phio’s Innovative RNAi Technology Platform
-
Phio Pharmaceuticals Reports 2023 Year End Financial Results and Provides Business Update
-
Phio Pharmaceuticals Presenting Data Showing INTASYL May Result in More Effective Cell Therapy for Hematological Malignancies
Trading Information
- Previous Close Price
- $0.80
- Day Range
- $0.77–0.84
- 52-Week Range
- $0.55–6.85
- Bid/Ask
- $0.70 / $0.78
- Market Cap
- $3.54 Mil
- Volume/Avg
- 3,233 / 423,371
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Phio Pharmaceuticals Corp is a clinical-stage biotechnology company whose proprietary INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. The Company is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body’s ability to fight cancer, without the need for specialized formulations or drug delivery systems.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 9
- Website
- https://www.phiopharma.com
Valuation
Metric
|
PHIO
|
---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.37 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
PHIO
Financial Strength
Metric
|
PHIO
|
---|---|
Quick Ratio | 5.20 |
Current Ratio | 5.71 |
Interest Coverage | — |
Quick Ratio
PHIO
Profitability
Metric
|
PHIO
|
---|---|
Return on Assets (Normalized) | −96.77% |
Return on Equity (Normalized) | −120.91% |
Return on Invested Capital (Normalized) | −119.47% |
Return on Assets
PHIO
Biotechnology Industry Comparables
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Vgghtggf | Zdbr | $567.0 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Ppwqpmw | Tmnbmzj | $108.1 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Jlscptzq | Kzjqpy | $105.3 Bil | |
MRNA
| Moderna Inc | Ndlswhnn | Snzf | $47.0 Bil | |
ARGX
| argenx SE ADR | Vsfyglg | Phr | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Vkjbfgm | Frds | $22.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Scvzzqfm | Zmmpkk | $19.1 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Qhmstjbjz | Mgfdhz | $15.5 Bil | |
RPRX
| Royalty Pharma PLC Class A | Nqbhmymnn | Tffcc | $12.6 Bil | |
INCY
| Incyte Corp | Pclvrkrd | Yvljts | $12.0 Bil |